of patient-reported nonadherence equivalent to major defaultingon  $20–30\%$   of days would be needed to accord with comparable nonadherence estimates of  $6\%$   of patients made by their physicians (Table 2).  

These self-reports of incomplete adherence with prescribed treatments for BPD in one-third of patients are unverified, but the risk of under-reporting may be limited by the very sensitive standard applied in an effort to detect the “worst case” for incomplete treatment-adherence. In addition to the self-reported, recent incomplete treatment-adherence just noted,  $32.9\%$   [137/417]of patients also reported having discontinued all recommended medications for BPD at some point in the past, without informing their physicians. Leading reasons given for such patientinitiated discontinuation of treatment, among 130 patients providing such information, ranked: (a) not needing it any longer  $(22.3\%)>(6)$  no longer wanting totakeit  $(18.5\%)\!>\!(\mathrm{c})$  sideeffects  $(13.1\%])>(\mathrm{d})$  feeling better at the time  $(10.8\%)$  

The rate of reported major defaulting in the past  $(32.9\%)$   and the rate of missing recent single doses  $(33.8\%)$   is similar, and many cases of previous and current nonadherence  $(45.0\%)$  involved thesame persons. Both rates represent about one-third of all treated patients with BPD sampled, indicating that some degree of treatment-nonadherence may be quite  prevalent  among   contemporary   American BPD patients. The apparently large disparity between physicians’ impressions and patient self-reports is noteworthy, but may reflect differences in definitions of “nonadherence,” such that physicians self-defined nonadherence was likely to reflect clinically important levels of missed dosing over undefined periods of risk, whereas patients were asked about even single missed doses within 10 recent days.  

# Patientassessments ofillness andits treatment  

When asked a general question about major frustrations of having BPD, patients cited factors related to the illness as well as its treatment (Table 3). Most commonly cited major burdens involving  $\geq40\%$  of 423 patients providing such data were: mood swings  $(66.4\%)>$  depression  $(56.3\%)>$  needfordailyself- medication  $(51.1\%)>$  stigma  of  beingconsidered mentally ill  $(43.5\%)>$  uncertaininterpersonalrelationships  $(40.4\%)\ge m e\epsilon$  dication  side-effects  $(40.2\%)$  Prominent adverse effects associated with treatmentnonadherence, as identified by the 145 patients with self-reported nonadherence,  ranked: weight-gain  $(58.5\%)\ge$  excessive sedation  $(54.2\%)\!>\!p$  hysicalawkwardnessortremor  $(33.1\%)$  

Table 3. Major frustrations reported by BPD patients   


<td><table  border="1"><thead><tr><td><b>Characteristic</b></td><td><b>n (%)</b></td></tr></thead><tbody><tr><td>Illness-relatedfactors</td><td></td></tr><tr><td>Mood swings</td><td>281 (66.4)</td></tr><tr><td>Depressions</td><td>238 (56.3)</td></tr><tr><td>Others’ perceptions/stigma</td><td>184 (43.5)</td></tr><tr><td>Problems with trust/relationships/social interactions</td><td>171 (40.4)</td></tr><tr><td>Holding down a job</td><td>152 (35.9)</td></tr><tr><td>Hospitalization</td><td>118 (27.9)</td></tr><tr><td>Highs of mood</td><td>115 (27.2)</td></tr><tr><td>Lack of information</td><td>26 (6.15)</td></tr><tr><td>Treatment-relatedfactors</td><td></td></tr><tr><td>Taking medication every day</td><td>216 (51.1)</td></tr><tr><td>Medication side-effects</td><td>170 (40.2)</td></tr><tr><td>Cost of treatment</td><td>3 (0.71)</td></tr><tr><td>Miscellaneous factors</td><td></td></tr><tr><td>Other</td><td>34 (8.04)</td></tr></tbody></table></td>


Responding patients  $N\!=\!423$  ，  $98.6\%$  )cited four major frustrations/ person (1708/423).  

# Physician assessments of treatment  

When psychiatrists were asked to report improvements in treatments for BPD patients needed to increase acceptance and adherence to treatment, the most common response was the need for better mood-stabilizationin  $48.0\%$   of their 429 patients. In addition, they identified freedom from weight-gain as important  for treatment-acceptance  among  $29.1\%$  of their patients, and improvement of treatmentunresponsivedepressionin  $30.8\%$  .They also estimated that at least  $59.0\%$   of their BPD patients had experienced adverse effects of psychotropic medications at some time in the past, that adverse effects were ofcurrentconcernto  $14.0\%$  of patients (60/429), and were considered by their physicians to be severe in  $15.0\%$  (9/60) of that subgroup. Psychiatrists reported further that  $30.5\%$  of their 429 BPD patients had experienced weight-gain in association with current treatment, with substantial prevalence of hyperlipidemia  $(19.1\%)$  and diabetes  $(8.62\%)$  andidentified these as problems of particular clinical concern.  

# Univariate analyses of factors associatedwith treatment-nonadherence  

We compared treatment-nonadherent with treatmentadherent patients on a list of factors identified in the PSF and PRF questionnaires, which yielded a total of 59 variables tentatively related totreatment adherence, based on initial univariate comparisons  $p\leq0.10)$  , and 43 significantly(  $p<0.05)$  associated  